Skip to main content
Top
Published in:

26-06-2023 | Dupilumab | Original Research

Analyses of Dupilumab-Related Ocular Adverse Drug Reactions Using the WHO’s VigiBase

Authors: Eri Hirai, Tomoko Haruki, Takashi Baba, Dai Miyazaki

Published in: Advances in Therapy | Issue 9/2023

Login to get access

Abstract

Introduction

Dupilumab is a drug that inhibits the action of interleukin (IL)-4 and IL-13 and is a potent therapeutic drug for allergic diseases such as atopic dermatitis. Although its use has been associated with significant ocular adverse drug reactions (ADRs), the IL-4 and IL-13 inhibition may also have favorable therapeutic effects. The aim of this study was to determine the disease spectrum in which the use of dupilumab may have been associated with an increase or decrease of ocular ADRs.

Methods

We searched the World Health Organization’s VigiBase for ADRs associated with the use of dupilumab for data up to 12 June 2022. The number of all ADRs that were retrieved was compared with the number of ocular ADRs associated with the use of dupilumab. Disproportionate reporting was assessed by calculating the information component (IC) values and odds ratios.

Results

Since the introduction of dupilumab, 100,267 ADRs have been reported. Of all the ADRs associated with dupilumab, 28,522 ADRs were ocular complications, and it ranked fourth in the ocular complications by organ level. By assessments of the IC for age ≤ 44 years, the most significantly associated ADRs were dry eye followed by blepharitis including eyelid crusting and dryness and conjunctivitis. Crusting and dryness of the eyelids were the most significant ADRs for all age groups. Other ocular ADRs reported include meibomian gland dysfunction, keratitis, glaucoma, and retinal disorders. In contrast, periorbital edema, neuro-ophthalmic disorders, optic neuritis, and macular edema were significantly reduced by the use of dupilumab.

Conclusions

Dupilumab-related ADRs included an increase or decrease of various ocular disorders. The results indicate that dupilumab also has potential therapeutic effects.
Literature
1.
go back to reference Thaci D, Simpson EL, Beck LA, et al. Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial. Lancet. 2016;387(10013):40–52.CrossRefPubMed Thaci D, Simpson EL, Beck LA, et al. Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial. Lancet. 2016;387(10013):40–52.CrossRefPubMed
2.
go back to reference Munoz-Bellido FJ, Moreno E, Davila I. Dupilumab: a review of present indications and off-label uses. J Investig Allergol Clin Immunol. 2022;32(2):97–115.CrossRefPubMed Munoz-Bellido FJ, Moreno E, Davila I. Dupilumab: a review of present indications and off-label uses. J Investig Allergol Clin Immunol. 2022;32(2):97–115.CrossRefPubMed
4.
go back to reference Simpson EL, Bieber T, Guttman-Yassky E, et al. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med. 2016;375(24):2335–48.CrossRefPubMed Simpson EL, Bieber T, Guttman-Yassky E, et al. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med. 2016;375(24):2335–48.CrossRefPubMed
5.
go back to reference Brumfiel CM, Patel MH, Zirwas MJ. Development of psoriasis during treatment with dupilumab: a systematic review. J Am Acad Dermatol. 2022;86(3):708–9.CrossRefPubMed Brumfiel CM, Patel MH, Zirwas MJ. Development of psoriasis during treatment with dupilumab: a systematic review. J Am Acad Dermatol. 2022;86(3):708–9.CrossRefPubMed
6.
go back to reference Jo CE, Finstad A, Georgakopoulos JR, Piguet V, Yeung J, Drucker AM. Facial and neck erythema associated with dupilumab treatment: a systematic review. J Am Acad Dermatol. 2021;84(5):1339–47.CrossRefPubMed Jo CE, Finstad A, Georgakopoulos JR, Piguet V, Yeung J, Drucker AM. Facial and neck erythema associated with dupilumab treatment: a systematic review. J Am Acad Dermatol. 2021;84(5):1339–47.CrossRefPubMed
7.
go back to reference Chretien B, Dolladille C, Alexandre J, et al. Dupilumab-associated arthralgia: an observational retrospective study in VigiBase(®). Br J Dermatol. 2021;185(2):464–5.CrossRefPubMed Chretien B, Dolladille C, Alexandre J, et al. Dupilumab-associated arthralgia: an observational retrospective study in VigiBase(®). Br J Dermatol. 2021;185(2):464–5.CrossRefPubMed
8.
go back to reference Kychygina A, Cassagne M, Tauber M, et al. Dupilumab-associated adverse events during treatment of allergic diseases. Clin Rev Allergy Immunol. 2022;62(3):519–33.CrossRefPubMed Kychygina A, Cassagne M, Tauber M, et al. Dupilumab-associated adverse events during treatment of allergic diseases. Clin Rev Allergy Immunol. 2022;62(3):519–33.CrossRefPubMed
9.
go back to reference Halling AS, Loft N, Silverberg JI, Guttman-Yassky E, Thyssen JP. Real-world evidence of dupilumab efficacy and risk of adverse events: a systematic review and meta-analysis. J Am Acad Dermatol. 2021;84(1):139–47.CrossRefPubMed Halling AS, Loft N, Silverberg JI, Guttman-Yassky E, Thyssen JP. Real-world evidence of dupilumab efficacy and risk of adverse events: a systematic review and meta-analysis. J Am Acad Dermatol. 2021;84(1):139–47.CrossRefPubMed
10.
go back to reference Hansen PM, Tollenaere MAX, Hedengran A, et al. IL-4 and IL-13 both contribute to the homeostasis of human conjunctival goblet cells in vitro. Allergy. 2022;77(8):2555–8.CrossRefPubMed Hansen PM, Tollenaere MAX, Hedengran A, et al. IL-4 and IL-13 both contribute to the homeostasis of human conjunctival goblet cells in vitro. Allergy. 2022;77(8):2555–8.CrossRefPubMed
11.
go back to reference Huang SC, Smith AM, Everts B, et al. Metabolic reprogramming mediated by the mTORC2-IRF4 signaling axis is essential for macrophage alternative activation. Immunity. 2016;45(4):817–30.CrossRefPubMedPubMedCentral Huang SC, Smith AM, Everts B, et al. Metabolic reprogramming mediated by the mTORC2-IRF4 signaling axis is essential for macrophage alternative activation. Immunity. 2016;45(4):817–30.CrossRefPubMedPubMedCentral
12.
go back to reference Wollenberg A, Beck LA, de Bruin WM, et al. Conjunctivitis in adult patients with moderate-to-severe atopic dermatitis: results from five tralokinumab clinical trials. Br J Dermatol. 2022;186(3):453–65.CrossRefPubMed Wollenberg A, Beck LA, de Bruin WM, et al. Conjunctivitis in adult patients with moderate-to-severe atopic dermatitis: results from five tralokinumab clinical trials. Br J Dermatol. 2022;186(3):453–65.CrossRefPubMed
13.
go back to reference Mahroum N, Damiani G, Watad A, et al. Higher rates of COVID-19 but less severe infections reported for patients on dupilumab: a big data analysis of the World Health Organization VigiBase. Eur Rev Med Pharmacol Sci. 2021;25:5865–70.PubMed Mahroum N, Damiani G, Watad A, et al. Higher rates of COVID-19 but less severe infections reported for patients on dupilumab: a big data analysis of the World Health Organization VigiBase. Eur Rev Med Pharmacol Sci. 2021;25:5865–70.PubMed
14.
go back to reference Norén GN, Orre R, Bate A. A hit-miss model for duplicate detection in the WHO drug safety database. Proceeding of the eleventh ACM SIGKDD international conference on knowledge discovery in data mining - KDD '05. 2005:459–468. Norén GN, Orre R, Bate A. A hit-miss model for duplicate detection in the WHO drug safety database. Proceeding of the eleventh ACM SIGKDD international conference on knowledge discovery in data mining - KDD '05. 2005:459–468.
15.
go back to reference Blauvelt A, de Bruin-Weller M, Gooderham M, et al. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. Lancet. 2017;389(10086):2287–303.CrossRefPubMed Blauvelt A, de Bruin-Weller M, Gooderham M, et al. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. Lancet. 2017;389(10086):2287–303.CrossRefPubMed
16.
go back to reference de Bruin-Weller M, Thaçi D, Smith CH, et al. Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical trial (LIBERTY AD CAFÉ). Br J Dermatol. 2018;178(5):1083–101.CrossRefPubMed de Bruin-Weller M, Thaçi D, Smith CH, et al. Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical trial (LIBERTY AD CAFÉ). Br J Dermatol. 2018;178(5):1083–101.CrossRefPubMed
17.
go back to reference Worm M, Simpson EL, Thaci D, et al. Efficacy and safety of multiple dupilumab dose regimens after initial successful treatment in patients with atopic dermatitis: a randomized clinical trial. JAMA Dermatol. 2020;156(2):131–43.CrossRefPubMed Worm M, Simpson EL, Thaci D, et al. Efficacy and safety of multiple dupilumab dose regimens after initial successful treatment in patients with atopic dermatitis: a randomized clinical trial. JAMA Dermatol. 2020;156(2):131–43.CrossRefPubMed
19.
go back to reference Bachert C, Mannent L, Naclerio RM, et al. Effect of subcutaneous dupilumab on nasal polyp burden in patients with chronic sinusitis and nasal polyposis: a randomized clinical trial. JAMA. 2016;315(5):469–79.CrossRefPubMed Bachert C, Mannent L, Naclerio RM, et al. Effect of subcutaneous dupilumab on nasal polyp burden in patients with chronic sinusitis and nasal polyposis: a randomized clinical trial. JAMA. 2016;315(5):469–79.CrossRefPubMed
20.
go back to reference Castro M, Corren J, Pavord ID, et al. Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma. N Engl J Med. 2018;378(26):2486–96.CrossRefPubMed Castro M, Corren J, Pavord ID, et al. Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma. N Engl J Med. 2018;378(26):2486–96.CrossRefPubMed
21.
go back to reference Hirano I, Dellon ES, Hamilton JD, et al. Efficacy of dupilumab in a phase 2 randomized trial of adults with active eosinophilic esophagitis. Gastroenterology. 2020;158(1):111-22.e10.CrossRefPubMed Hirano I, Dellon ES, Hamilton JD, et al. Efficacy of dupilumab in a phase 2 randomized trial of adults with active eosinophilic esophagitis. Gastroenterology. 2020;158(1):111-22.e10.CrossRefPubMed
22.
go back to reference Rabe KF, Nair P, Brusselle G, et al. Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma. N Engl J Med. 2018;378(26):2475–85.CrossRefPubMed Rabe KF, Nair P, Brusselle G, et al. Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma. N Engl J Med. 2018;378(26):2475–85.CrossRefPubMed
23.
go back to reference Wenzel S, Castro M, Corren J, et al. Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting beta2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial. Lancet. 2016;388(10039):31–44.CrossRefPubMed Wenzel S, Castro M, Corren J, et al. Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting beta2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial. Lancet. 2016;388(10039):31–44.CrossRefPubMed
24.
go back to reference Atherton HC, Jones G, Danahay H. IL-13-induced changes in the goblet cell density of human bronchial epithelial cell cultures MAP kinase and phosphatidylinositol 3-kinase regulation. Am J Physiol Lung Cell Mol Physiol. 2003;285:730–9.CrossRef Atherton HC, Jones G, Danahay H. IL-13-induced changes in the goblet cell density of human bronchial epithelial cell cultures MAP kinase and phosphatidylinositol 3-kinase regulation. Am J Physiol Lung Cell Mol Physiol. 2003;285:730–9.CrossRef
25.
go back to reference Jun I, Kim BR, Park SY, et al. Interleukin-4 stimulates lipogenesis in meibocytes by activating the STAT6/PPARgamma signaling pathway. Ocul Surf. 2020;18(4):575–82.CrossRefPubMed Jun I, Kim BR, Park SY, et al. Interleukin-4 stimulates lipogenesis in meibocytes by activating the STAT6/PPARgamma signaling pathway. Ocul Surf. 2020;18(4):575–82.CrossRefPubMed
27.
go back to reference Thyssen JP. Could conjunctivitis in patients with atopic dermatitis treated with dupilumab be caused by colonization with demodex and increased interleukin-17 levels? Br J Dermatol. 2018;178(5):1220.CrossRefPubMed Thyssen JP. Could conjunctivitis in patients with atopic dermatitis treated with dupilumab be caused by colonization with demodex and increased interleukin-17 levels? Br J Dermatol. 2018;178(5):1220.CrossRefPubMed
29.
go back to reference Takakuwa K, Hamanaka T, Mori K, et al. Atopic glaucoma: clinical and pathophysiological analysis. J Glaucoma. 2015;24(9):662–8.CrossRefPubMed Takakuwa K, Hamanaka T, Mori K, et al. Atopic glaucoma: clinical and pathophysiological analysis. J Glaucoma. 2015;24(9):662–8.CrossRefPubMed
30.
go back to reference Chen D, Peng C, Ding XM, et al. Interleukin-4 promotes microglial polarization toward a neuroprotective phenotype after retinal ischemia/reperfusion injury. Neural Regen Res. 2022;17(12):2755–60.CrossRefPubMedPubMedCentral Chen D, Peng C, Ding XM, et al. Interleukin-4 promotes microglial polarization toward a neuroprotective phenotype after retinal ischemia/reperfusion injury. Neural Regen Res. 2022;17(12):2755–60.CrossRefPubMedPubMedCentral
31.
go back to reference Baba T, Miyazaki D, Inata K, et al. Role of IL-4 in bone marrow driven dysregulated angiogenesis and age-related macular degeneration. Elife. 2020;9:e54257.CrossRefPubMedPubMedCentral Baba T, Miyazaki D, Inata K, et al. Role of IL-4 in bone marrow driven dysregulated angiogenesis and age-related macular degeneration. Elife. 2020;9:e54257.CrossRefPubMedPubMedCentral
33.
go back to reference Chernykh VV, Varvarinsky EV, Smirnov EV, Chernykh DV, Trunov AN. Proliferative and inflammatory factors in the vitreous of patients with proliferative diabetic retinopathy. Indian J Ophthalmol. 2015;63(1):33–6.CrossRefPubMedPubMedCentral Chernykh VV, Varvarinsky EV, Smirnov EV, Chernykh DV, Trunov AN. Proliferative and inflammatory factors in the vitreous of patients with proliferative diabetic retinopathy. Indian J Ophthalmol. 2015;63(1):33–6.CrossRefPubMedPubMedCentral
34.
go back to reference Yamada T, Komiya I, Miyahara Y, et al. Effect of methimazole treatment for 2 years on circulating IL-4, IgE, TBII, and TSAb in patients with hyperthyroid Graves’ disease. Endocr J. 2006;53(6):783–8.CrossRefPubMed Yamada T, Komiya I, Miyahara Y, et al. Effect of methimazole treatment for 2 years on circulating IL-4, IgE, TBII, and TSAb in patients with hyperthyroid Graves’ disease. Endocr J. 2006;53(6):783–8.CrossRefPubMed
35.
go back to reference Chen B, Tsui S, Boeglin WE, Douglas RS, Brash AR, Smith TJ. Interleukin-4 induces 15-lipoxygenase-1 expression in human orbital fibroblasts from patients with Graves disease. Evidence for anatomic site-selective actions of Th2 cytokines. J Biol Chem. 2006;281(27):18296–306.CrossRefPubMed Chen B, Tsui S, Boeglin WE, Douglas RS, Brash AR, Smith TJ. Interleukin-4 induces 15-lipoxygenase-1 expression in human orbital fibroblasts from patients with Graves disease. Evidence for anatomic site-selective actions of Th2 cytokines. J Biol Chem. 2006;281(27):18296–306.CrossRefPubMed
36.
go back to reference Alves-Leon SV, Pimentel ML, Sant’Anna G, Malfetano FR, Estrada CD, Quirico-Santos T. Immune system markers of neuroinflammation in patients with clinical diagnose of neuromyelitis optica. Arq Neuropsiquiatr. 2008;66(3B):678–84.CrossRefPubMed Alves-Leon SV, Pimentel ML, Sant’Anna G, Malfetano FR, Estrada CD, Quirico-Santos T. Immune system markers of neuroinflammation in patients with clinical diagnose of neuromyelitis optica. Arq Neuropsiquiatr. 2008;66(3B):678–84.CrossRefPubMed
37.
go back to reference Seyfizadeh N, Kazemi T, Farhoudi M, et al. Association of IL-13 single nucleotide polymorphisms in Iranian patients to multiple sclerosis. Am J Clin Exp Immunol. 2014;3(3):124–9.PubMedPubMedCentral Seyfizadeh N, Kazemi T, Farhoudi M, et al. Association of IL-13 single nucleotide polymorphisms in Iranian patients to multiple sclerosis. Am J Clin Exp Immunol. 2014;3(3):124–9.PubMedPubMedCentral
38.
go back to reference Noren GN, Hopstadius J, Bate A. Shrinkage observed-to-expected ratios for robust and transparent large-scale pattern discovery. Stat Methods Med Res. 2013;22(1):57–69.CrossRefPubMed Noren GN, Hopstadius J, Bate A. Shrinkage observed-to-expected ratios for robust and transparent large-scale pattern discovery. Stat Methods Med Res. 2013;22(1):57–69.CrossRefPubMed
39.
go back to reference Bihan K, Lebrun-Vignes B, Funck-Brentano C, Salem JE. Uses of pharmacovigilance databases: an overview. Therapie. 2020;75(6):591–8.CrossRefPubMed Bihan K, Lebrun-Vignes B, Funck-Brentano C, Salem JE. Uses of pharmacovigilance databases: an overview. Therapie. 2020;75(6):591–8.CrossRefPubMed
Metadata
Title
Analyses of Dupilumab-Related Ocular Adverse Drug Reactions Using the WHO’s VigiBase
Authors
Eri Hirai
Tomoko Haruki
Takashi Baba
Dai Miyazaki
Publication date
26-06-2023
Publisher
Springer Healthcare
Published in
Advances in Therapy / Issue 9/2023
Print ISSN: 0741-238X
Electronic ISSN: 1865-8652
DOI
https://doi.org/10.1007/s12325-023-02573-3

Other articles of this Issue 9/2023

Advances in Therapy 9/2023 Go to the issue

Keynote webinar | Spotlight on adolescent vaping

  • Live
  • Webinar | 29-01-2025 | 18:00 (CET)

Live: Wednesday 29th January, 18:00-19:30 CET

Growing numbers of young people are using e-cigarettes, despite warnings of respiratory effects and addiction. How can doctors tackle the epidemic, and what health effects should you prepare to manage in your clinics?

Prof. Ann McNeill
Dr. Debbie Robson
Benji Horwell
Developed by: Springer Medicine
Join the webinar

Keynote webinar | Spotlight on modern management of frailty

Frailty has a significant impact on health and wellbeing, especially in older adults. Our experts explain the factors that contribute to the development of frailty and how you can manage the condition and reduce the risk of disability, dependency, and mortality in your patients.

Prof. Alfonso Cruz-Jentoft
Prof. Barbara C. van Munster
Prof. Mirko Petrovic
Developed by: Springer Medicine
Watch now

A quick guide to ECGs

Improve your ECG interpretation skills with this comprehensive, rapid, interactive course. Expert advice provides detailed feedback as you work through 50 ECGs covering the most common cardiac presentations to ensure your practice stays up to date. 

PD Dr. Carsten W. Israel
Developed by: Springer Medizin
Start the cases

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Read more